Paperpal Prime Logo

Lung Cancer : Impact Factor & More

eISSN: 1872-8332pISSN: 0169-5002

Aims and Scope of Lung Cancer

Lung Cancer is a peer-reviewed medical journal published by Elsevier originally published on behalf of the International Association for the Study of Lung Cancer (until 2006). As of 2015, it is published on behalf of the International Lung Cancer Consortium, the European Thoracic Oncology Platform, and the British Thoracic Oncology Group. It includes original research and review articles of relevance to lung cancer. Less

Key Metrics

CiteScore
9.4
Eigenfactor
0.01 - 0.05
H-Index
141
Impact Factor
5 - 10
SJR
Q1Oncology
SNIP
1.44
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Lung Cancer

Lung Cancer Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • SJR SJR
Overview
Publisher ELSEVIER IRELAND LTD
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year1985
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Lung Cancer ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Lung Cancer

Lack of methodological clarity in the report of the association of cannabis use and lung cancer.
  • 1 Jul 2026
  • Lung cancer (Amsterdam, Netherlands)
Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studies.
  • 1 Jul 2026
  • Lung cancer (Amsterdam, Netherlands)
Immune-related markers define clinically relevant prognostic subgroups in thymic epithelial tumors.
  • 1 Jul 2026
  • Lung cancer (Amsterdam, Netherlands)
Upfront management of brain metastases in oncogene‑addicted NSCLC - An EORTC survey.
  • 1 Jul 2026
  • Lung cancer (Amsterdam, Netherlands)
Vebreltinib plus EGFR-TKI for EGFR-mutated NSCLC with MET-driven resistance: A real-world study of Chinese patients.
  • 1 Jul 2026
  • Lung cancer (Amsterdam, Netherlands)
Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer.
  • 1 Jul 2026
  • Lung cancer (Amsterdam, Netherlands)
Lack of methodological clarity in the report of the association of cannabis use and lung cancer.
  • 1 Jul 2026
  • Lung cancer (Amsterdam, Netherlands)
Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studies.
  • 1 Jul 2026
  • Lung cancer (Amsterdam, Netherlands)
Immune-related markers define clinically relevant prognostic subgroups in thymic epithelial tumors.
  • 1 Jul 2026
  • Lung cancer (Amsterdam, Netherlands)
Upfront management of brain metastases in oncogene‑addicted NSCLC - An EORTC survey.
  • 1 Jul 2026
  • Lung cancer (Amsterdam, Netherlands)
Vebreltinib plus EGFR-TKI for EGFR-mutated NSCLC with MET-driven resistance: A real-world study of Chinese patients.
  • 1 Jul 2026
  • Lung cancer (Amsterdam, Netherlands)
Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer.
  • 1 Jul 2026
  • Lung cancer (Amsterdam, Netherlands)

FAQs on Lung Cancer